CytoMed Therapeutics Ltd(GDTC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:00 PM ET (Korea 11/7 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.23 | Insider Own | 56.1% | Shs Outstand | 11.9M | Perf Week | -6.51% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | 1.72% | Shs Float | 5.2M | Perf Month | -9.09% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 0.27% | Short Float | 0.37% | Perf Quarter | 7.36% |
| Income | -0.00B | P/S | 40.65 | EPS this Y | - | Inst Trans | -5.52% | Short Ratio | 0.98 | Perf Half Y | 10.13% |
| Sales | 0.00B | P/B | 2.67 | EPS next 5Y | - | ROA | -45.59% | Short Interest | 0.02M | Perf YTD | -35.66% |
| Book/sh | 0.32 | P/C | 8.99 | EPS past 3/5Y | -8.01% -226.97% | ROE | -57.78% | 52W High | -72.29% ($3.10) | Perf Year | -57.89% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -65.87% | 52W Low | 26.3% ($0.68) | Perf 3Y | -78.84% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 3.91% | Gross Margin | -286.22% | Volatility(W/M) | 8.24% 11.32% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 38.85 | Sales Y/Y TTM | 49.09% | Oper. Margin | -1339.92% | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.64 | EPS Q/Q | 20.63% | Profit Margin | -1076.73% | RSI (14) | 44.14 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.64 | Sales Q/Q | 4.53% | SMA20 | -3.43% ($0.89) | Beta | 0.05 | Target Price | $4.16 |
| Payout | - | Debt/Eq | 0.09 | Earnings | - | SMA50 | -4.25% ($0.9) | Rel Volume | 0.47 | Prev Close | $0.88 |
| Employees | 42 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | - | SMA200 | -12.07% ($0.98) | Avg Volume(3M) | 0.02M | Price | $0.86 |
| IPO | 2023/4/14 | Option/Short | No/Yes | Trades | 43 | Volume | 9,293 | Change | -2.39% |
🧪 Cytomed Therapeutics () is a Singapore-based clinical-stage biotech company developing gamma-delta (γδ) T cell-based allogeneic ("off-the-shelf") cellular immunotherapies. It is clinically advancing its proprietary CAR-γδ T cell therapy CTM-N2D and its non-genetically-modified γδ T cell therapy CTM-GDT for both solid tumors and hematologic cancers, and has recently expanded its pipeline through the acquisition of TC BioPharm's gamma-delta T cell technology TCB-002 — making it a small-cap Asian biotech play.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded less than usual. That is 47% of its average volume.
GDTC has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4,065. Peers typically go for $917.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -78.8%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
It ranks #502 of 597 in the industry
Based on market cap of $10M.
AZR#500 Azora Therapeutics Inc $11M PER - 
AEON#501 AEON Biopharma Inc $10M PER - GDTC#502 CytoMed Therapeutics Ltd $10M PER - 
ICU#503 SeaStar Medical Holding Corp $10M PER - 
INTS#504 Intensity Therapeutics Inc $10M PER - 
FAQ
What kind of company is GDTC?
GDTC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of GDTC?
The market cap of GDTC is approximately $10M, ranking 5,411 within its sector.
What is the 52-week high and low for GDTC?
GDTC has recorded a 52-week high of $3.10 and a low of $0.68.
